Novartis Presents Results of Kesimpta (ofatumumab) in P-III (ASCLEPIOS I/II) and (ALITHIOS) Open-Label Extension Trial for RMS at EAN 2022
- The P-III (ASCLEPIOS I/II) trials and the (ALITHIOS) OLE trial evaluating Kesimpta in patients with RMS
- The results showed that 78.8% of patients treated continuously with Kesimpta achieved NEDA-3 vs 51.8% of those who switched from teriflunomide to Kesimpta in the extension phase after 4yrs. of treatment
- The additional analysis from (ASCLEPIOS I/II) showed improvements in CPS vs those treated with teriflunomide. The results were based on the prior presented efficacy data from (ASCLEPIOS I/II) & (ALITHIOS) trials which demonstrated consistent differences in cumulative relapses, MRI lesion activity & risk of disability worsening b/w those who were continuously treated with Kesimpta vs those who switched at a later time
Ref: Novartis | Image: Novartis
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at firstname.lastname@example.org.